<DOC>
	<DOCNO>NCT00528957</DOCNO>
	<brief_summary>The purpose study assess safety efficacy switch tenofovir disoproxil fumarate ( TDF ) compare continue stavudine zidovudine maintain virologic suppression HIV-1 infect child .</brief_summary>
	<brief_title>Safety Efficacy Switching From Stavudine Zidovudine Tenofovir DF HIV-1 Infected Children</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Major Documented laboratory diagnosis HIV1 infection Plasma HIV1 RNA &lt; 400 copies/mL Currently stable stavudine zidovudine contain antiretroviral therapy regimen least 12 week Naive tenofovir DF Inclusion Criteria First 96Week Extension Completed 48 week treatment Arm 1 Arm 2 study &lt; 18 year age ( start extension ) Participants initially randomize Arm 2 give option replace stavudine zidovudine tenofovir DF 96week extension investigator 's discretion , investigator determines tenofovir DF safe beneficial participant . Inclusion Criteria Second , Third , Fourth 96Week Extension Completed treatment study drug first extension phase &lt; 18 year age start extension . This inclusion criterion applicable region tenofovir DF commercially available treatment HIV1 infection adult . Participants receive ongoing therapy follow Nephrotoxic agent Systemic chemotherapeutic agent Systemic corticosteroid Interleukin 2 ( IL 2 ) immunomodulating agent Investigational agent Pregnant lactate participant Evidence gastrointestinal malabsorption syndrome chronic nausea vomiting may confer inability receive orally administer medication Current alcohol substance abuse judge investigator potentially interfere participant compliance Malignancy cutaneous Kaposi 's sarcoma ( KS ) basal cell carcinoma . Active , serious infection ( HIV1 infection ) require parenteral antibiotic therapy within 15 day prior screen Prior history significant renal disease ( ie , nephrotic syndrome , renal dysgenesis , polycystic kidney disease , congenital nephrosis ) Prior history significant bone disease ( ie , osteomalacia , chronic osteomyelitis , osteogenesis imperfecta , osteochondroses , multiple bone fracture )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Phase 3</keyword>
	<keyword>Randomized , Open-Label</keyword>
	<keyword>Treatment-Experienced</keyword>
	<keyword>Highly Active Antiretroviral Therapy</keyword>
	<keyword>HIV</keyword>
	<keyword>Tenofovir DF</keyword>
	<keyword>Pediatrics</keyword>
</DOC>